Suppr超能文献

过氧化物酶体增殖物激活受体γ共激活因子-1α 通过 PPARγ 依赖性 WNT/β-连环蛋白/丙酮酸脱氢酶激酶同工酶 1 轴抑制糖酵解抑制肝癌转移。

PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.

机构信息

State Key Laboratory of Oncogenes and Related GenesShanghai Cancer InstituteRenji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina.

Liver Cancer InstituteZhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education)Fudan UniversityShanghaiChina.

出版信息

Hepatology. 2021 Feb;73(2):644-660. doi: 10.1002/hep.31280.

Abstract

BACKGROUND AND AIMS

Peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator-1α (PGC1α) is a key regulator of mitochondrial biogenesis and respiration. PGC1α is involved in the carcinogenesis, progression, and metabolic state of cancer. However, its role in the progression of hepatocellular carcinoma (HCC) remains unclear.

APPROACH AND RESULTS

In this study, we observed that PGC1α was down-regulated in human HCC. A clinical study showed that low levels of PGC1α expression were correlated with poor survival, vascular invasion, and larger tumor size. PGC1α inhibited the migration and invasion of HCC cells with both in vitro experiments and in vivo mouse models. Mechanistically, PGC1α suppressed the Warburg effect through down-regulation of pyruvate dehydrogenase kinase isozyme 1 (PDK1) mediated by the WNT/β-catenin pathway, and inhibition of the WNT/β-catenin pathway was induced by activation of PPARγ.

CONCLUSIONS

Low levels of PGC1α expression indicate a poor prognosis for HCC patients. PGC1α suppresses HCC metastasis by inhibiting aerobic glycolysis through regulating the WNT/β-catenin/PDK1 axis, which depends on PPARγ. PGC1α is a potential factor for predicting prognosis and a therapeutic target for HCC patients.

摘要

背景与目的

过氧化物酶体增殖物激活受体-γ(PPARγ)共激活因子-1α(PGC1α)是线粒体生物发生和呼吸的关键调节因子。PGC1α 参与癌症的发生、发展和代谢状态。然而,其在肝细胞癌(HCC)进展中的作用尚不清楚。

方法和结果

在本研究中,我们观察到 PGC1α 在人 HCC 中下调。一项临床研究表明,PGC1α 低表达与生存率降低、血管侵犯和肿瘤体积增大相关。PGC1α 通过 WNT/β-连环蛋白通路下调丙酮酸脱氢酶激酶同工酶 1(PDK1)抑制 HCC 细胞的迁移和侵袭,而 PPARγ 的激活诱导了 WNT/β-连环蛋白通路的抑制。

结论

PGC1α 低表达表明 HCC 患者预后不良。PGC1α 通过调节 WNT/β-连环蛋白/PDK1 轴抑制有氧糖酵解来抑制 HCC 转移,这依赖于 PPARγ。PGC1α 是预测预后的潜在因素,也是 HCC 患者的治疗靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验